Tag: Wuhan Zhong Yuan Rui De Biologics
CSL to buy majority stake in a leading Chinese plasma fractionator
Australian biotech firm CSL has agreed to acquire an 80% stake in China’s plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biologics (Ruide) in...
Featured Article
Reducing downtime through real-time shop floor insights with Minitab’s Prolink
Unplanned downtime remains one of the most costly – and often misunderstood – challenges on the manufacturing floor.
